Lori M. Reilly is Executive Vice-President for Policy & Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Her primary focus is overseeing PhRMA’s development of legislative and policy analysis and research studies on a range of health care issues including 340B, Food and Drug Administration (FDA) policy issues, the Independent Payment Advisory Board (IPAB), direct-to-consumer (DTC) advertising/marketing and promotion, and comparative effectiveness research. Ms. Reilly works to develop and implement legislative, regulatory and political strategies to successfully navigate the ever-changing federal health care landscape.
In addition to her public policy work, Ms. Reilly is a frequent presenter on industry-related issues and is an industry spokesperson. Ms. Reilly testified before the House Energy and Commerce Subcommittee on Health to discuss the importance of the reauthorization of the pediatric exclusivity program and the Food and Drug Administration Globalization Act.
Prior to joining PhRMA, she was counsel at the U.S. House of Representatives Committee on Commerce. And before joining the House Commerce Committee, Ms. Reilly was Chief of Staff/Counsel to Rep. Jon Christensen, a member of the House Ways and Means Committee.
Ms. Reilly is currently a Board Member of the Personalized Medicine Coalition and is a member of the Editorial Advisory Board of The Food and Drug Law Institute’s Policy Forum. In addition, she is on the Board of Humanitarian Relief International, an organization dedicated to supporting charitable and disaster relief efforts.
Ms. Reilly received a B.A. in Political Science from the University of Nebraska-Lincoln where she graduated with Honors, and a J.D. from the University of Nebraska College of Law. She is a Member of the Virginia Bar and currently resides in Alexandria, Virginia with her husband and their four children.